About this Research Topic
The landscape of neuroendocrine neoplasms (NENs) is changing. Up until around 30 years ago, treatment had either been surgical or medical. Since 1994, however, treatment with radiolabeled somatostatin analogues, so-called peptide-receptor radionuclide therapy (PRRT), has been a possibility. A randomized trial (NETTER-1) comparing PRRT with high-dose somatostatin analogue treatment in patients with well differentiated advanced small-gut neuroendocrine tumours (NET) showed a significant effect of PRRT on both progression-free survival and overall survival. The same results have not yet been shown in NENs of other origin. Additional studies have reported positive effects of PRRT treatment on the quality of life. Further research has also demonstrated the therapeutic value of PRRT, which includes advances on grade 3 NENs, or its combination with chemotherapy. At present, the side effects of PRRT remain to be fully elucidated. Both myelodysplastic syndrome and severe renal failure have been described, but how common they are, and whether they can be prevented, remains unknown.
The scope of this Research Topic is therefore to present new advances within diagnosis, treatment, and prognosis of NENs, with a special focus on PRRT. We wish to investigate other effects (both beneficial and side-effects) of this emerging treatment in tumors with different origin (gastro-entero pancreatic, lung and pheochromocytoma). We would also like to explore whether we can implement PRRT in the treatment of NEN G3, or if it is solely for NET G1 and G2.
In this Research Topic, we welcome reviews, original research, case reports, and clinical trials which focus on both clinical, translational, epidemiological and basic science in order to highlight the advances in this area.
The scope of this Research Topic is therefore to present new advances within diagnosis, treatment, and prognosis of NENs, with a special focus on PRRT. We wish to investigate other effects (both beneficial and side-effects) of this emerging treatment in tumors with different origin (gastro-entero pancreatic, lung and pheochromocytoma). We would also like to explore whether we can implement PRRT in the treatment of NEN G3, or if it is solely for NET G1 and G2.
In this Research Topic, we welcome reviews, original research, case reports, and clinical trials which focus on both clinical, translational, epidemiological and basic science in order to highlight the advances in this area.
Keywords: Diagnosis, medical treatment, radionuclide treatment, prognosis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
